Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05182385
Recruitment Status : Recruiting
First Posted : January 10, 2022
Last Update Posted : January 10, 2022
Sponsor:
Collaborator:
University Hospital Schleswig-Holstein
Information provided by (Responsible Party):
Nicola Goekbuget, Goethe University

Brief Summary:
This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.

Condition or disease Intervention/treatment Phase
ALL, Recurrent, Adult Drug: Blinatumomab Drug: Venetoclax Phase 1 Phase 2

Detailed Description:

Transfer of patients to alloHSCT after one cycle or after a subsequent cycle is considered as per protocol discontinuation and as premature treatment discontinuation.

There will be a safety follow-up visit at 30 days after end of the last infusion. There will be efficacy follow-up until 6 months after end of therapy. In patients scheduled for SCT the 30-day safety-visit may be performed at the latest time point possible before initiation of subsequent treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase I/II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Actual Study Start Date : December 15, 2021
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 30, 2023


Arm Intervention/treatment
Experimental: hematological relapse

Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:

  • Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy
  • Untreated first relapse of BCP-ALL with first remission duration < 12 months or
  • Second or greater relapse of BCP-ALL or refractory relapse or
  • Relapse of BCP-ALL any time after allogeneic HSCT
Drug: Blinatumomab

All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).

All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)

Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type.

Other Name: blincyto

Drug: Venetoclax

In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.

In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.

Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type.

Other Name: Venclyxto

Experimental: molecular relapse

Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:

-Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.1% if in first or second remission of BCP-ALL

Drug: Blinatumomab

All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).

All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)

Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type.

Other Name: blincyto

Drug: Venetoclax

In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.

In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.

Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type.

Other Name: Venclyxto




Primary Outcome Measures :
  1. Phase I/ part 1: Maximum tolerated dose (MTD) [ Time Frame: through study part I completion, anticipated after 1 year ]

    The primary endpoint of the part I dose escalation part will be maximum tolerated dose (MTD).

    The combination of Venetoclax and Blinatumomab will be evaluated for tolerability in a 3+3 design. In a 3+3 design, three patients will form a cohort. Each cohort will receive a higher cumulative dose of Venetoclax in pre-defined dose escalation steps (see table below). If one patient experiences dose limiting toxicity (DLT), the cohort will be expanded to six patients.

    If two or more of these 6 patients experience a DLT, the next lower Venetoclax dose will be defined as maximum tolerated dose (MTD). If 0/3 or <2/6 patients in a cohort experience a DLT, the next dose escalation cohort will be opened. In case of ≥ 2 DLTs at the dose level 1, dose level -1 will be used as a fallback option. The DLT evaluation period is defined as the first 49 days after initiation of Venetoclax in cycle 1 (i.e. C1D-7 to C1D42)


  2. Phase II/ part 2: rate of complete molecular remissions (Mol-CR) [ Time Frame: after one cycle of treatment (up to 43 days) ]

    The primary efficacy measure of the part II expansion part will be the rate of complete molecular remissions (Mol-CR) after one cycle of Blinatumomab and Venetoclax.

    - Mol-CR is defined as MRD negativity with a sensitivity of at least 10E-04 Disease status will be assessed by bone marrow and peripheral blood analysis at the end of Cycle 1. Bone marrow aspiration is required at any time on study in case peripheral blood analysis is suspicious for progression of disease.



Secondary Outcome Measures :
  1. Rate of composite complete remissions (cCR) [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]

    rate of composite complete remissions (cCR) including CR without complete hematologic regeneration (CRh) and CR with incomplete recovery of peripheral blood counts (CRi) after one treatment cycle

    • CR is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (i.e. platelets ≥ 100.000/μl, and ANC

      ≥ 1.000/μl), and no evidence of (extramedullary) disease

    • CRh is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (i.e. 50.000/μl < platelets < 100.000/μl, and 500/μl < ANC < 1.000/μl), and no evidence of (extramedullary) disease
    • CRi is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts (i.e. platelets ≥ 50.000/μl or ANC ≥ 1.000/μl, and no evidence of (extramedullary) disease

  2. Overall response rate (ORR) [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]
    overall response rate (ORR), including rate of CR, CRh, CRi, and rate of partial remission (PR)

  3. Remission duration [ Time Frame: at 1 year and 2 years after EOT ]
    median and probability of Remission duration at 1 year and 2 years

  4. Event-free survival (EFS) [ Time Frame: at 1 year and 2 years after EOT ]

    o EFS time will be calculated from the time of starting on-protocol therapy (C1D-7) until the date of (a) disease assessment indicating relapse after having achieved CR/CRh/CRi or (b) disease assessment indicating refractory disease after one or two cylces or (c) death, whichever occurs first. All subjects failing to achieve CR/CRh/CRi after the first cycle will be reassessed after two cycles if applicable.

    Subjects alive and relapse-free at the time of analysis will be censored on their last disease assessment date.


  5. Overall survival (OS) [ Time Frame: at 1 year and 2 years after EOT ]
    median OS times will be calculated from the time of starting on-protocol therapy (C1D-7) until death due to any cause. Subjects still alive at the time of analysis will be censored at the date last known to be alive.

  6. Overall response rate (ORR) [ Time Frame: after one cycle of treatment (up to 43 days) ]

    including CR, CRh, CRi and partial remission (PR)

    o PR is defined as having 5% < blasts < 20% in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (i.e. platelets > 50.000/μl, and ANC > 500/μl)


  7. CR rates in comparson to Blinatumomab monotherapy [ Time Frame: after one cycle of treatment (up to 43 days) ]
    CR rates in comparson with historical cohorts treated with Blinatumomab alone with inverse probability of treatment weighting (IPTW) using the propensity score

  8. Duration of MRD response [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]
    Probability of continuous MRD response and complete MRD response and duration of MRD response

  9. Measurement of Quality of Life [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]
    Measurement of Quality of Life with EORTC instruments (EORTC QLQ C30 and EQ-5D) at different time-points during treatment

  10. Rate of allogeneic stem cell transplantation [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]
    Proportion of patients who undergo allogeneic stem cell transplantation

  11. Relapse localisations [ Time Frame: until End of Follow-Up (up to 6 months after EOT) ]
    Frequency of different relapse localisations in proportion to total hematological relapses


Other Outcome Measures:
  1. Treatment realisation 1 [ Time Frame: until end of treatment (up to 1+12 weeks) ]
    incidence of treatment interruptions

  2. Treatment realisation 2 [ Time Frame: until end of treatment (up to 1+12 weeks) ]
    total dose reductions

  3. Treatment realisation 3 [ Time Frame: until end of treatment (up to 1+12 weeks) ]
    total treatment discontinuations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure
  2. Age ≥ 18 years
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  4. Availability of patient-specific molecular MRD markers of immunoglobulin/T-cell receptor gene rearrangementsas assessed by PCR with a sensitivity of at least 10E-04
  5. Diagnosis of Philadelphia negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:

    • Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy
    • Untreated first relapse of BCP-ALL with first remission duration < 12 months or
    • Second or greater relapse of BCP-ALL or refractory relapse or
    • Relapse of BCP-ALL any time after allogeneic HSCT or
  6. Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.1% if in first or second remission of BCP-ALL
  7. Negative pregnancy test < 7 days before first study drug in women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they fulfil at least one of the following criteria:

    1. Post-menopausal (i.e. 12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml
    2. Post-operative after bilateral ovariectomy with or without hysterectomy
    3. Continuous and correct application of a contraception method with a Pearl index of < 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from initial study drug administration until at least 3 months after the last dose of study drug. A hormonal contraception method must always be combined with a barrier method (e.g. condom)
    4. Sexual abstinence
    5. Vasectomy of the sexual partner
  8. Ability to understand and willingness to sign a written informed consent
  9. Willingness to participate in the registry of the German Multicenter Study Group for Adult ALL (GMALL)

Exclusion Criteria:

  1. Patients with diagnosis of Philadelphia positive BCP-ALL according to WHO classifiation
  2. Patients with diagnosis of Burkitt´s Leukemia according to WHO classification
  3. Patients with extramedullary relapse; non-bulky lymph node (< 7.5 cm diameter) involvement will be accepted
  4. Patients with CNS involvement at relapse (as determined by CSF analysis)
  5. Patients with suspected or histologically confirmed testicular involvement at relapse
  6. Current autoimmune disease of any kind or history of autoimmune disease with potential CNS involvement
  7. Patients with Philadelphia-positive BCP-ALL still receiving TKI
  8. Prior or concomitant therapy with BH3 mimetics
  9. Prior therapy with anti CD19 therapy, unless administered in MRD-positive setting (i.e. with bone marrow blasts ≤ 5%)
  10. Treatment with any of the following within 7 days prior to the first dose of study drug: strong cytochrome P450 3A (CYP3A) inhibitors, moderate or strong CYP3A inducers
  11. Intake of any of the following within 3 days prior to the first dose of study drug: grapefruit, grapefruit products, Seville oranges or star fruit
  12. Presence of Graft-versus-Host Disease (GvHD) and/or on immunosuppressant medication within 2 weeks before start of protocol-specified therapy
  13. Radiation, chemotherapy (with the exception of prephase therapy), or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1 or radio-immunotherapy 4 weeks prior to Cycle 1 Day 1.
  14. Major surgery within 2 weeks of first dose of study drug
  15. Patients who are pregnant or lactating
  16. Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety
  17. Unstable cardiovascular function:

    • Symptomatic ischemia, or
    • Uncontrolled clinically significant conduction abnormalities (1st degree AV block or asymptomatic LAFB/RBBB will not be excluded), or
    • Congestive heart failure (CHF) of NYHA Class ≥3, or
    • Myocardial infarction (MI) within 3 months
  18. Evidence of clinically significant uncontrolled condition(s) including, but not limited to: Uncontrolled and/or active systemic infection (viral, bacterial or fungal), chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti- HBs antibody (anti-HBs) positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) or blood transfusions may participate.
  19. Known human immunodeficiency virus (HIV) infection (HIV testing is not required)
  20. Patients unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI dysfunction that could interfere with absorption of study treatment
  21. Adequate hepatic function per local laboratory reference range as follows: Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0X ULN, Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
  22. Severe renal dysfunction: estimated creatinine clearance of < 20 mL/min, measured in 24 hour urine or calculated using the formula of Cockroft and Gault
  23. History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. History of CNS leukemia that is controlled at relapse may be enrolled in this study.
  24. History of malignancy other than ALL within 5 years prior to start of protocol-specified therapy with the exception of:

    • Malignancy treated with curative intent and with no known active disease present for 2 years before enrollment and felt to be at low risk for recurrence by the treating physician including
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
    • Adequately treated breast ductal carcinoma in situ without evidence of disease
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
  25. Current autoimmune disease or history of autoimmune disease with potential CNS involvement
  26. Live vaccination within 2 weeks before the start of study treatment
  27. Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation
  28. Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
  29. Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study(s). Thirty days is calculated from day 1 of protocol-specified therapy
  30. Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject's and Investigator's knowledge.
  31. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  32. Woman of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they fulfil at least one of the following criteria:

    • Post-menopausal (i.e. 12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml
    • Post-operative after bilateral ovariectomy with or without hysterectomy
    • Continuous and correct application of a contraception method with a Pearl index of < 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from initial study drug administration until at least 3 months after the last dose of study drug. A hormonal contraception method must always be combined with a barrier method (e.g. condom)
    • Sexual abstinence
    • Vasectomy of the sexual partner
  33. Male who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception while receiving protocol-specified therapy and for at least an additional 3 months after the last dose of protocol-specified therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05182385


Contacts
Layout table for location contacts
Contact: GMALL Study Center +49 (0)69 - 6301 ext 6366 gmall@em.uni-frankfurt.de

Locations
Layout table for location information
Germany
University Hospital of Frankfurt (Main) Recruiting
Frankfurt (Main), Hessen, Germany, 60590
Contact: GMALL Study Center    +49696301 ext 6366    gmall@em.uni-frankfurt.de   
Principal Investigator: Nicola Gökbuget, Dr. med.         
UKSH-Kiel Recruiting
Kiel, Germany
Contact: Lars Fransecky, Dr.         
Sponsors and Collaborators
Goethe University
University Hospital Schleswig-Holstein
Investigators
Layout table for investigator information
Principal Investigator: Nicola Goekbuget, MD GMALL-Study-Group
Layout table for additonal information
Responsible Party: Nicola Goekbuget, Principal Investigator, Goethe University
ClinicalTrials.gov Identifier: NCT05182385    
Other Study ID Numbers: GMALL-BLIVEN
2021-001384-25 ( EudraCT Number )
First Posted: January 10, 2022    Key Record Dates
Last Update Posted: January 10, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nicola Goekbuget, Goethe University:
ALL
acute lymphoblastic leukemia
MRD positive
minimal residual disease
blinatumomab
venetoclax
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Venetoclax
Blinatumomab
Antineoplastic Agents